Table 1.
Women with oral ET use at baseline and at follow-up | Women with no ET use at baseline and no ET use at follow-up | |
---|---|---|
n=324 | n=382 | |
Age (years)* | 56.5 (7.6) | 58.7 (9.0) |
Race/ethnicity* | ||
Caucasian | 66 | 53 |
African-American | 16 | 28 |
Hispanic | 13 | 16 |
Asian | 4 | 3 |
Type of menopause* | ||
Bilateral oophorectomy | 42 | 20 |
Natural menopause | 39 | 67 |
Age ≥ 55 years and hysterectomy | 19 | 16 |
Years since final menstrual period | 14 (9) | 15 (10) |
Baseline weight (kg)* | 87.6 (17.8) | 91.0 (19.7) |
Baseline waist circumference (cm)* | 101 (14) | 104 (14) |
Baseline BMI (kg/m2)* | 33.3 (6.5) | 34.6 (6.8) |
Baseline fasting insulin levels (IU/l)* | 23.4 (12.0) | 26.4 (16.0) |
Baseline fasting plasma glucose (mg/dl)* | 104 (7) | 107 (8) |
Baseline 2-hour glucose | 166 (18) | 164 (17) |
Baseline follicle stimulating hormone (IU/l)* | 34.8 (22.5) | 55.3 (26.6) |
Baseline sex hormone binding globulin (nmol/l)* | 85.3 (77.0) | 33.2 (18.3) |
Baseline total estradiol (pg/ml)* | 17.6 (14.8) | 8.5 (8.0) |
Baseline bioavailable estradiol (pg/ml)* | 8.6 (9.4) | 6.0 (6.4) |
Means (SD) or percentages shown; medians (interquartile ranges or IQR) shown for sex hormones.
indicates significant difference (p<0.05) between ET users and non-users.